Dalteparin sodium

Dalteparin sodium
Clinical data
Trade names Fragmin
AHFS/Drugs.com International Drug Names
Pregnancy
category
  • AU: C
  • US: B (No risk in non-human studies)
    Routes of
    administration
    subcutaneous
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Bioavailability 81-93%
    Elimination half-life 3-5 hours subcutaneous; 2.1-2.3 hours IV
    Excretion Renal
    Identifiers
    CAS Number
    DrugBank
    ChemSpider
    • none
    UNII
    KEGG

    Dalteparin is a low molecular weight heparin. It is marketed as Fragmin by Pfizer Inc. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism. It is normally administered by self-injection.

    The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than warfarin in reducing the risk of recurrent embolic events.[1] Dalteparin is not superior to unfractionated heparin in preventing blood clots.[2]

    Heparins are cleared by the kidneys, but studies have shown that dalteparin does not accumulate even if kidney function is reduced.[3]

    References

    1. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003). "Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer". N Engl J Med. 349 (2): 146–53. doi:10.1056/NEJMoa025313. PMID 12853587.
    2. The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2011). "Dalteparin versus unfractionated heparin in critically ill patients". doi:10.1056/NEJMoa1014475.
    3. Douketis J, Cook D, Meade M, et al. (2008). "Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin". Arch Intern Med. 168 (16): 1805–1812. doi:10.1001/archinte.168.16.1805. PMID 18779469.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.